Neuronetics, Inc. Common Stock (STIM) Stock Price

STIMStock

$2.98−15.00%52W

Market Cap$227.07M

P/E—

PEG Ratio—

Div yield—

Beta1.17

STIM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)98.17%

Price vs S&P 500 (4W)51.49%

VGM Score64.43

Book Value / Share (Quarterly)$0.19

P/TBV (Annual)22.35x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)31.76%

Cash Flow / Share (Quarterly)$-0.20

Price vs S&P 500 (YTD)97.46%

Gross Margin (TTM)47.96%

Net Profit Margin (TTM)-24.48%

EPS (TTM)$-0.55

10-Day Avg Trading Volume4.71M

EPS Excl Extra (TTM)$-0.55

Revenue Growth (5Y)24.81%

EPS (Annual)$-0.59

ROI (Annual)-44.22%

Gross Margin (Annual)48.48%

Net Profit Margin (5Y Avg)-48.04%

Cash / Share (Quarterly)$0.19

Revenue Growth QoQ (YoY)7.75%

ROA (Last FY)-27.55%

Revenue Growth TTM (YoY)69.52%

EBITD / Share (TTM)$-0.39

ROE (5Y Avg)-104.40%

Operating Margin (TTM)-19.76%

Cash Flow / Share (Annual)$-0.31

P/B Ratio18.84x

P/B Ratio (Quarterly)7.61x

Net Income / Employee (Annual)$-59,300

EV / Revenue (TTM)1.97x

Net Interest Coverage (TTM)-3.65x

ROA (TTM)-27.13%

EPS Incl Extra (Annual)$-0.59

Current Ratio (Annual)2.02x

Quick Ratio (Quarterly)1.25x

3-Month Avg Trading Volume2.40M

52-Week Price Return-15.00%

Revenue / Employee (TTM)$230,400

Tangible BV / Share (Quarterly)$0.06

P/S Ratio (Annual)1.68x

Asset Turnover (Annual)1.05x

52-Week High$3.71

Operating Margin (5Y Avg)-43.93%

EPS Excl Extra (Annual)$-0.59

CapEx CAGR (5Y)1.87%

26-Week Price Return109.42%

Quick Ratio (Annual)1.68x

13-Week Price Return142.86%

Total Debt / Equity (Annual)2.94x

Current Ratio (Quarterly)1.67x

Enterprise Value$298.01M

Revenue / Share Growth (5Y)-2.85%

Asset Turnover (TTM)1.11x

Book Value / Share Growth (5Y)-24.65%

Revenue / Employee (Annual)$226,700

Inventory Turnover (Annual)17.92x

Pretax Margin (Annual)-26.24%

Cash / Share (Annual)$0.41

3-Month Return Std Dev138.71%

Gross Margin (5Y Avg)69.69%

Net Income / Employee (TTM)$-56,400

ROE (Last FY)-174.27%

Net Interest Coverage (Annual)-3.25x

EPS Basic Excl Extra (Annual)$-0.59

Receivables Turnover (TTM)7.22x

Total Debt / Equity (Quarterly)4.62x

EPS Incl Extra (TTM)$-0.55

Receivables Turnover (Annual)7.49x

ROI (TTM)-43.86%

P/S Ratio (TTM)1.65x

Pretax Margin (5Y Avg)-48.06%

Revenue / Share (Annual)$2.26

Tangible BV / Share (Annual)$0.06

Price vs S&P 500 (52W)-33.31%

Year-to-Date Return109.42%

5-Day Price Return-8.25%

EPS Normalized (Annual)$-0.59

ROA (5Y Avg)-27.70%

Net Profit Margin (Annual)-26.15%

Month-to-Date Return45.96%

Cash Flow / Share (TTM)$-1.10

EBITD / Share (Annual)$-0.42

Operating Margin (Annual)-21.08%

LT Debt / Equity (Annual)2.94x

ROI (5Y Avg)-39.01%

LT Debt / Equity (Quarterly)4.62x

EPS Basic Excl Extra (TTM)$-0.55

P/TBV (Quarterly)22.35x

P/B Ratio (Annual)4.22x

Inventory Turnover (TTM)17.97x

Pretax Margin (TTM)-24.55%

Book Value / Share (Annual)$0.32

Price vs S&P 500 (13W)140.06%

Beta1.17x

Revenue / Share (TTM)$2.18

ROE (TTM)-164.68%

52-Week Low$0.80

vGradeC

gGradeB

mGradeB

vgmGradeB

STIM Earnings Surprise History

Q2 25-0.15est. -0.08

Q3 25-0.13est. -0.13

Q4 25-0.10est. -0.11

Q1 26-0.15est. -0.17

Q2 26-0.04est. -0.12

STIM Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.11

4.20

Industry Peers — Surgical & Medical Instruments(140)

Symbol	Value Score	Growth Score	Momentum Score	Price
STIMNeuronetics, Inc. Common Stock	C	B	B	$2.98
SYKStryker Corporation	C	B	C	$330.59
MMM3M Company	C	D	B	$179.37
BSXBoston Scientific Corp.	C	B	D	$49.86
BDXBecton, Dickinson and Co.	B	D	B	$189.78
MDLNMedline Inc. Class A common stock	C	D	C	$35.64
RMDResMed Inc.	C	B	C	$236.59
DXCMDexCom, Inc.	D	B	B	$89.16
WSTWest Pharmaceutical Services, Inc.	D	C	B	$348.48
SOLVSolventum Corporation	C	C	B	$91.61
BAXBaxter International Inc.	B	D	B	$26.29
PENPenumbra, Inc.	D	C	C	$324.37
GMEDGLOBUS MEDICAL INC	B	B	C	$82.96
GKOSGlaukos Corporation	F	A	A	$181.39
PODDInsulet Corporation	C	A	D	$143.05
STVNStevanato Group S.p.A.	D	C	B	$22.70
TFXTeleflex Incorporated	B	F	B	$140.18
MMSIMerit Medical Systems Inc	C	B	B	$91.09
MMEDMiniMed Group, Inc. Common Stock	—	—	A	$18.92
HAEHaemonetics Corporation	C	C	A	$108.32
ICUIICU Medical Inc	C	D	B	$182.24
HTFLHeartflow, Inc. Common Stock	—	A	A	$49.89
IRTCiRhythm Holdings, Inc. Common Stock	F	A	C	$123.09
PLSEPulse Biosciences, Inc Common Stock (DE)	F	—	A	$49.00
ATRCAtriCure, Inc.	D	B	A	$48.68
UFPTUFP Technologies Inc	C	B	B	$304.21
NVCRNovoCure Limited Ordinary Shares	D	C	C	$17.62
LMATLeMaitre Vascular, Inc.	C	B	D	$78.97
INSPInspire Medical Systems, Inc.	B	B	B	$61.07
KMTSKestra Medical Technologies, Ltd. Common Stock	F	A	B	$26.92
TNDMTandem Diabetes Care, Inc.	D	C	B	$21.58
ATECAlphatec Holdings, Inc.	D	B	C	$9.33
DRTSAlpha Tau Medical Ltd. Ordinary Shares	—	—	A	$14.70
IARTIntegra LifeSciences Holdings	B	D	C	$16.79
AORTArtivion, Inc.	C	C	C	$26.38
PRCTPROCEPT BioRobotics Corporation Common Stock	C	A	D	$21.60
IRMDiRadimed Corporation	D	B	C	$87.87
BVSBioventus Inc. Class A Common Stock	B	C	A	$14.08
SGPSpyGlass Pharma, Inc. Common Stock	—	—	B	$26.60
SIBNSI-BONE, Inc. Common Stock	D	B	B	$19.54
BBNXBeta Bionics, Inc. Common Stock	D	A	A	$19.34
SSIISS Innovations International Inc. Common Stock	F	A	D	$3.55
ANGOAngioDynamics, Inc.	C	D	B	$15.95
KIDSOrthoPediatrics Corp. Common Stock	C	B	B	$24.50
MDXGMiMedx Group, Inc	C	D	C	$4.34
DCTHDelcath Systems Inc	D	B	A	$16.92
BWAYBrainsway Ltd. American Depositary Shares	F	A	C	$14.43
CERSCerus Corp	D	C	B	$2.72
TCMDTactile Systems Technology, Inc.	B	B	C	$23.58
CLPTClearPoint Neuro, Inc. Common Stock	F	A	B	$16.96
NPCENeuropace, Inc. Common Stock	D	C	C	$14.16

About Neuronetics, Inc. Common Stock

Neuronetics Inc is a medical device company specializing in transcranial magnetic stimulation (TMS) therapy for psychiatric disorders. Its flagship product, the NeuroStar Advanced Therapy System, is a non-invasive, office-based treatment that uses MRI-strength magnetic fields to stimulate brain regions associated with mood regulation. NeuroStar is approved to treat major depressive disorder (MDD) and offers an alternative to conventional psychiatric therapies that may have significant side effects or efficacy limitations.